Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 1/20 | 0.33 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22128275 | 1.00 | CCR9 (0.33) | CCR9OXER1POLBCYP3A4HTR2A | |
| SCHEMBL22128243 | 0.85 | — | — | |
| SCHEMBL22128242 | 0.85 | — | — | |
| SCHEMBL22128169 | 0.84 | CCR9 (0.33) | CCR9HTR2AHTR2C | |
| SCHEMBL22128170 | 0.84 | CCR9 (0.33) | CCR9HTR2AHTR2C | |
| SCHEMBL22128370 | 0.78 | AKR1B1 (0.32) | — | |
| SCHEMBL22128371 | 0.78 | AKR1B1 (0.32) | — | |
| SCHEMBL22128218 | 0.77 | B3GNT2 (0.40) | — | |
| SCHEMBL22128221 | 0.77 | B3GNT2 (0.40) | — | |
| SCHEMBL28664000 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-02 | — | — | US | disclosed |
| CN-113498342-A | Compounds involved in synergistic binding and uses thereof | 锐新医药公司 | 2021-10-12 | — | — | CN | disclosed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | CCR9 2100/4885OXER1 4073/4885POLB 2323/4885 |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | CCR9 2100/4885OXER1 4073/4885POLB 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.